MCLA-128

DRUG3 trials

Sponsors

Partner Therapeutics Inc., Merus N.V., Partner Therapeutics, Inc.

Conditions

Breast CancerCholangiocarcinomaColorectal CancerHead and Neck CancerMetastatic Castration-resistant Prostate CancerNRG1 FusionNSCLC Harboring NRG1 FusionNon Small Cell Lung Cancer

Phase 1

A Phase I/II Study of MCLA-128, a full length IgG1 Bispecific Antibody Targeting HER2 and HER3, in Patients with Solid Tumors (eNRGy)

RecruitingCTIS2024-512358-78-00

Partner Therapeutics Inc.Solid Tumors

Start: 2015-01-20Target: 341Updated: 2025-12-19

Phase 2

Study Evaluating Zenocutuzumab in Patients With or Without Molecularly Defined Cancers

TerminatedNCT05588609

Partner Therapeutics, Inc.Metastatic Castration-resistant Prostate Cancer, NSCLC Harboring NRG1 Fusion

Start: 2022-11-17End: 2025-07-03Updated: 2026-04-27

Unknown Phase

Early Access Program Providing HER2/HER3 Bispecific Antibody, MCLA-128, for a Patient With Advanced NRG1-Fusion Positive Solid Tumor

Merus N.V.Breast Cancer, Cholangiocarcinoma, Colorectal Cancer +8

Updated: 2025-05-20